Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze

被引:153
作者
Holmes, A
Kinney, JW
Wrenn, CC
Li, Q
Yang, RJ
Ma, L
Vishwanath, J
Saavedra, MC
Innerfield, CE
Jacoby, AS
Shine, J
Iismaa, TP
Crawley, JN
机构
[1] NIMH, Sect Behav Genom, Bethesda, MD 20892 USA
[2] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA
[3] Garvan Inst Med Res, Sydney, NSW, Australia
关键词
galanin; GAL-R1; receptor; mouse; anxiety; stress; norepinephrine;
D O I
10.1038/sj.npp.1300164
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The neuropeptide galanin coexists with norepinephrine and serotonin in neural systems mediating emotion. Previous findings suggested that galanin modulates anxiety-related behaviors in rodents. Three galanin receptor subtypes have been cloned; however, understanding their functions has been limited by the lack of galanin receptor subtype-selective ligands. To study the role of the galanin GAL-RI receptor subtype in mediating anxiety-related behavior, we generated mice with a null mutation in the Galrl gene, GAL-Rl -/- are viable and show no abnormalities in health, neurological reflexes, motoric functions, or sensory abilities. On a battery of tests for anxiety-like behavior, GAL-R I -/- showed increased anxiety-like behavior on the elevated plus-maze test. Anxiety-related behaviors on the light/dark exploration, emergence, and open field tests were normal in GAL-RI -/-. This test-specific anxiety-like phenotype was confirmed in a second, independent cohort of GAL-RI null mutant mice and +/+ controls, Principal components factor analysis of behavioral scores from 279 mice suggested that anxiety-like behavior on the elevated plus-maze was qualitatively distinct from behavior on other tests in the battery, In addition, exposure to the elevated plus-maze produced a significantly greater neuroendocrine response than exposure to the light/dark exploration test, as analyzed in normal C57BU6J mice. These behavioral findings in the first galanin receptor null mutant mouse are consistent with the hypothesis that galanin exerts anxiolytic actions via the GAL-R I receptor under conditions of relatively high stress.
引用
收藏
页码:1031 / 1044
页数:14
相关论文
共 100 条
[1]   Learned fear, emotional reactivity and fear of heights:: A factor analytic map from a large F2 intercross of Roman rat strains [J].
Aguilar, R ;
Gil, L ;
Flint, J ;
Gray, JA ;
Dawson, GR ;
Driscoll, P ;
Giménez-Llort, L ;
Escorihuela, RM ;
Fernández-Teruel, A ;
Tobeña, A .
BRAIN RESEARCH BULLETIN, 2002, 57 (01) :17-26
[2]   TYROSINE-HYDROXYLASE AND GALANIN MESSENGER-RNA LEVELS IN LOCUS-CERULEUS NEURONS ARE INCREASED FOLLOWING RESERPINE ADMINISTRATION [J].
AUSTIN, MC ;
COTTINGHAM, SL ;
PAUL, SM ;
CRAWLEY, JN .
SYNAPSE, 1990, 6 (04) :351-357
[3]   Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress [J].
Bale, TL ;
Contarino, AB ;
Smith, GW ;
Chan, R ;
Gold, LH ;
Sawchenko, PE ;
Koob, GF ;
Vale, WW ;
Lee, KF .
NATURE GENETICS, 2000, 24 (04) :410-414
[4]   REGULATION OF THE RELEASE OF COEXISTING NEUROTRANSMITTERS [J].
BARTFAI, T ;
IVERFELDT, K ;
FISONE, G ;
SERFOZO, P .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1988, 28 :285-310
[5]   COMPARISON OF DIFFERENT BEHAVIORAL-TEST SITUATIONS USED IN PSYCHOPHARMACOLOGY FOR MEASUREMENT OF ANXIETY [J].
BELZUNG, C ;
LEPAPE, G .
PHYSIOLOGY & BEHAVIOR, 1994, 56 (03) :623-628
[6]   ANXIOLYTIC-LIKE ACTION OF CENTRALLY ADMINISTERED GALANIN [J].
BING, O ;
MOLLER, C ;
ENGEL, JA ;
SODERPALM, B ;
HEILIG, M .
NEUROSCIENCE LETTERS, 1993, 164 (1-2) :17-20
[7]   Galanin receptor subtypes [J].
Branchek, TA ;
Smith, KE ;
Gerald, C ;
Walker, MW .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (03) :109-116
[8]  
Bremner JD, 1996, SYNAPSE, V23, P28, DOI 10.1002/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.3.CO
[9]  
2-4
[10]   POTENT EFFECTS OF HUMAN GALANIN IN MAN - GROWTH-HORMONE SECRETION AND VAGAL BLOCKADE [J].
CAREY, DG ;
IISMAA, TP ;
HO, KY ;
RAJKOVIC, IA ;
KELLY, J ;
KRAEGEN, EW ;
FERGUSON, J ;
INGLIS, AS ;
SHINE, J ;
CHISHOLM, DJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (01) :90-93